Registration Dossier

Diss Factsheets

Administrative data

Link to relevant study record(s)

Description of key information

Systemic availability is likely of one or several of the constituents or their metabolites. There are no experimental data to prove a bioaccumulating potential.

Key value for chemical safety assessment

Additional information

The substance is a multi-constituent product with a low water solubility (0.01 mg/L, calculated) and a log Pow of 7.62 (calculated).

The test item hydrolysis directly and quantitatively when it is solved in the buffer solutions. Thus the test item is not considered to be hydrolytically stable at pH 4, 7 and 9. The determination of the hydrolysis rate is not possible because of the very fast hydrolysis.

The following transformation products was detected: Tolyltriazole (CAS No. 29385-43-1). Formaldehyde (CAS No. 50-00-0), Bis(2-ethylhexyl)amine (CAS No. 106-20-7) were proposed as further degradation products.

Simulation of microbial metabolism suggests tolylbenzotriazole (TTZ) as the predominant metabolite (OECD Toolbox, version 2.0). Therefore it can be expected that cleavage of the bulky molecules already takes place in the gastro-intestinal tract to some extent presenting TTZ and alkylamines for an enhanced uptake and distribution. Systemic exposure could not be proven since compound-related findings were not evident other than stress-related effects seen in thymus and spleen. Clinical findings including mortality were observed suggesting uptake to some extent.

Metabolic behaviour is supposed to be similar for a structural analogue (see chapter 7.6.1 for details on molecule). It is postulated that this substance yields to the main metabolite methylbenzotriazole after gastro-intestinal and/or liver cleavage. This substance provides the data of the genotoxicity testing for potential clastogenicity (chromosome aberration).